Skip Navigation Links
SEARCH  



 
Bookmark and Share
Ascentage Pharma’s MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma
SUZHOU, China, and ROCKVILLE, MD, Sept 23, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepa...

Full "IntellAsia: Resources" article




Disclaimer | Terms Of Use And Privacy Statement


© Metals News. All rights reserved.